Orthofix ( (OFIX) ) has shared an update.
Orthofix reported record financial results for the fourth quarter and full-year 2024, with net sales increasing by 8% and 7% respectively, compared to the previous year. Despite a net loss of $29.1 million in the fourth quarter, the company achieved a significant improvement in cash flow and increased its long-term growth targets. Orthofix also announced the discontinuation of its M6 artificial disc product lines to focus on more profitable growth opportunities, aligning with its strategic focus on spinal fixation and deformity correction.
More about Orthofix
Orthofix Medical Inc. is a leading global medical technology company specializing in spine, orthopedics, and bone growth therapies. The company focuses on providing innovative solutions to improve patient outcomes and has a market focus on spinal fixation and deformity correction.
YTD Price Performance: 5.16%
Average Trading Volume: 180,509
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $693.6M
For detailed information about OFIX stock, go to TipRanks’ Stock Analysis page.